GlassScriptPhysician profile
Habib Barakat
NPI 1982660767
$8,691.90
in general payments reported to CMS, 2019-2025
44 companies · $1,456 in 2025
The $1,456 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,137 · 2020: $811 · 2021: $797 · 2022: $1,218 · 2023: $1,682 · 2024: $1,592 · 2025: $1,456.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,639 · Education: $90.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,639.15 |
| Education | $90.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,241.12 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,172.79 | 2019-2025 | Breztri, Tezspire, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $720.42 | 2019-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Actelion Pharmaceuticals US, INC. | $561.75 | 2019-2025 | Uptravi, Opsumit |
| Insmed, INC. | $453.77 | 2019-2025 | Arikayce |
| Regeneron Healthcare Solutions, INC. | $426.10 | 2019-2025 | Dupixent |
| Amgen INC. | $369.24 | 2021-2025 | Tezspire |
| Merck Sharp & Dohme LLC | $361.82 | 2021-2025 | Winrevair, Zerbaxa, Belsomra |
| Mallinckrodt Hospital Products INC. | $337.04 | 2020-2025 | Acthar |
| Takeda Pharmaceuticals U.S.A., INC. | $328.04 | 2020-2025 | Glassia |
| Baxter Healthcare | $305.25 | 2022-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System, Hillrom - Monarch Airway Clearance System |
| Eisai INC. | $249.93 | 2024-2025 | |
| Genzyme Corporation | $239.32 | 2019-2024 | |
| Ani Pharmaceuticals, INC. | $206.40 | 2022-2024 | Purified Cortrophin Gel |
| Lilly USA, LLC | $205.89 | 2020-2025 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $140.18 | 2019-2025 | Tyvaso, Tyvaso |
| Genentech USA, INC. | $122.91 | 2019-2023 | Xolair |
| Mylan Specialty L.P. | $117.50 | 2019-2024 | Yupelri |
| Irhythm Technologies, INC. | $116.67 | 2019 | |
| Jazz Pharmaceuticals INC. | $81.69 | 2021-2024 | Xywav |
| Pfizer INC. | $79.79 | 2019-2024 | |
| Sunovion Pharmaceuticals INC. | $78.06 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $72.62 | 2019-2021 | |
| Verona Pharma, INC. | $69.19 | 2025 | Ohtuvayre |
| Inspire Medical Systems, INC. | $66.45 | 2024-2025 | Inspire |
| Novartis Pharmaceuticals Corporation | $65.59 | 2019-2023 | |
| Teva Pharmaceuticals USA, INC. | $51.41 | 2021-2022 | |
| Masimo Corporation | $43.22 | 2020 | |
| Advanced Respiratory, INC | $40.07 | 2020-2021 | |
| Viatris Specialty LLC | $38.79 | 2025 | Yupelri |
| Mallinckrodt Enterprises LLC | $37.75 | 2019 | |
| Philips North America LLC | $33.21 | 2023-2024 | (Ak6) Vest Therapy |
| Novavax INC | $28.68 | 2023 | Novavax Covid-19 Vaccine, Adjuvanted |
| Circassia INC. | $26.24 | 2019 | |
| Inogen, INC. | $25.18 | 2024 | |
| Alexion Pharmaceuticals, INC. | $24.91 | 2024 | Ultomiris |
| Electromed, INC. | $24.28 | 2025 | Smartvest |
| Idorsia Pharmaceuticals US INC | $21.55 | 2023 | Quviviq |
| Paratek Pharmaceuticals, INC. | $21.53 | 2022 | |
| Vifor Pharma, INC. | $19.38 | 2024 | Zemaira |
| Resmed Corp | $18.88 | 2019 | |
| Pharming Healthcare, INC. | $16.16 | 2023 | Ruconest |
| Gilead Sciences, INC. | $15.66 | 2019 | |
| Pulmonx Corporation | $15.47 | 2024 | Chartis Catheter, Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Habib Barakat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.